Platelet Factor 4: An Inhibitor of Angiogenesis

Platelet factor 4 (PF4) is an antiangiogenic ELR-negative chemokine. PF4 inhibits endothelial cell proliferation and migration and angiogenesis in vitro and in vivo. Three different mechanisms have been proposed to explain PF4’s antiangiogenic effects. First, PF4 may bind proteoglycans and interfere with the proteoglycan-bystander effect on growth factor activity. Second, PF4 is able to interact directly with angiogenesis growth factors such as fibroblast growth factors or vascular endothelial growth factors and inhibits their interaction with cell surface receptors. Third, PF4 may activate cell surface receptors on endothelial cells and induce inhibitory signals. Recently, one such receptor, CXCR3-B, was identified. In cardiovascular disease, PF4 may possibly intervene in collateral vessel formation, plaque neovascularization, heparin-induced thrombocytopenia and stent endothelialization. Several PF4 fragments such as PF4-CTF and modified molecules have been made that exhibit antiangiogenesis properties and may serve as leads for further therapeutic development.

Platelet factor 4 - PF4 - angiogenesis - cardiovascular diseases - endothelial cells

REFERENCES

• 1 Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.  Trends Pharmacol Sci. 2002;  23 576-582
• 2 Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development.  Trends Mol Med. 2002;  8 483-489
• 3 Hagedorn M, Bikfalvi A. Target molecule for anti-angiogenesis therapy: from basic research to clinical trials.  Crit Rev Oncol Hematol. 2000;  34 89-110
• 4 Maione T E, Gray G S, Petro J et al.. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.  Science. 1990;  247 77-79
• 5 Sharpe R J, Byers H R, Scott C F, Bauer S I, Maione T E. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor-4.  J Natl Cancer Inst. 1990;  82 848-853
• 6 Maione T E, Gray G S, Hunt A J, Sharpe R J. Inhibition of tumor growth in mice by an analog of platelet factor-4 that lacks affinity for heparin and retains potent angiostatic activity.  Cancer Res. 1991;  51 2077-2083
• 7 Kolber D L, Knisely T L, Maione T E. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor-4.  J Natl Cancer Inst. 1995;  87 304-309
• 8 Tanaka T, Manome Y, Wen P, Kufe D, Fine H A. Viral vector-mediated transduction of a modified platelet factor-4 cDNA inhibits angiogenesis and tumor growth.  Nat Med. 1997;  3 437-442
• 9 Deuel T F, Keim P F, Farmer M, Heinrickson R L. Amino acid sequence of human platelet factor 4.  Proc Natl Acad Sci U S A. 1977;  74 2256-2258
• 10 Daly T, La Rosa G, Dolich S, Maione T, Cooper S, Broxmeyer H. High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin-8 and platelet factor-4.  J Biol Chem. 1995;  270 23282-23292
• 11 Zhang X, Chen L, Bancroft D L, Lai C K, Maione T M. Crystal structure of recombinant human platelet factor 4.  Biochemistry. 1994;  33 8361-8366
• 12 Stuckey J A, St Charles R, Edwards B. A model of the platelet factor-4 complex with heparin.  Proteins. 1992;  14 277-287
• 13 Gupta S K, Hassel T, Singh J P. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4.  Proc Natl Acad Sci U S A. 1995;  92 7799-7803
• 14 Jouan V, Canron X, Alemany M et al.. Modulation of in vitro angiogenesis by platelet factor-4 derived peptides and mechanism of action.  Blood. 1999;  94 984-993
• 15 Lozano R M, Redondo-Horcajo M, Jimenez M A et al.. Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity.  J Biol Chem. 2001;  276 35723-35734
• 16 Hagedorn M, Zilberberg L, Wilting J et al.. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.  Cancer Res. 2002;  62 6884-6890
• 17 Mayo K H, Ilyina E. A folding pathway for betapep-4 peptide 33mer: from unfolded monomers and beta-sheet sandwich dimers to well-structured tetramers.  Protein Sci. 1998;  7 358-368
• 18 Griffioen A W, van der Schaft D W, Barendsz-Janson A F et al.. Anginex, a designed peptide that inhibits angiogenesis.  Biochem J. 2001;  354 233-242
• 19 Mayo K H, van der Schaft D W, Griffioen A W. Designed β-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells.  Angiogenesis. 2001;  4 45-51
• 20 Dings R P, Arroyo M M, Lockwood N A et al.. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide.  Biochem J. 2003;  373 281-288
• 21 Butcher D J, Kowalska M A, Li S et al.. A natural motif approach to protein design: a synthetic leucine zipper peptide mimics the biological function of the platelet factor 4 protein.  FEBS Lett. 1997;  409 183-187
• 22 Gupta S K, Singh J P. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression.  J Cell Biol. 1994;  127 1121-1127
• 23 Perollet C, Han Z C, Savona C, Caen J P, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization.  Blood. 1998;  91 3289-3299
• 24 Feraud O, Cao Y, Vittet D. Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis.  Lab Invest. 2001;  81 1669-1681
• 25 Hansell P, Maione T E, Borgstrom P. Selective binding of platelet factor-4 to regions of active angiogenesis in vivo.  Am J Physiol. 1995;  269 829-836
• 26 Borgstrom P, Discipio R, Maione T E. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma.  Anticancer Res. 1998;  18 4035-4041
• 27 Hagedorn M, Zilberberg L, Lozano R M et al.. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.  FASEB J. 2001;  15 550-552
• 28 Dings R P, Yokoyama Y, Ramakrishnan S et al.. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin.  Cancer Res. 2003;  63 382-385
• 29 van der Schaft D W, Dings R P, de Lussanet Q G et al.. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models.  FASEB J. 2002;  16 1991-1993
• 30 Myler H A, West J L. Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM.  J Biochem (Tokyo). 2002;  131 913-922
• 31 Gentilini G, Kirschbaum N E, Augustine J A, Aster R H, Visentin G P. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1).  Blood. 1999;  93 25-33
• 32 Sulpice E, Bryckaert M, Lacour J, Contreres J O, Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway.  Blood. 2002;  100 3087-3094
• 33 Chadderton N S, Stringer S E. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate.  Int J Biochem Cell Biol. 2003;  35 1052-1055
• 34 Gengrinovitch S, Greenberg S M, Cohen T et al.. Platelet factor-4 inhibits the mitogenic activity of VEGF¹²¹ and VEGF¹⁶⁵ using several concurrent mechanisms.  J Biol Chem. 1995;  270 15059-15065
• 35 Lasagni L, Francalanci M, Annunziato F et al.. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.  J Exp Med. 2003;  197 1537-1549
• 36 Deindl E, Hoefer I E, Fernandez B et al.. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis.  Circ Res. 2003;  92 561-568
• 37 Couffinhal T, Silver M, Kearney M et al.. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE^-/- mice.  Circulation. 1999;  99 3188-3198
• 38 Moulton K S, Heller E, Konerding M A et al.. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.  Circulation. 1999;  99 1726-1732
• 39 Moulton K S, Vakili K, Zurakowski D et al.. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis.  Proc Natl Acad Sci U S A. 2003;  100 4736-4741
• 40 Van Belle E, Tio F O, Couffinhal T et al.. Stent endothelialization.  Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition. Circulation. 1997;  95 438-448
• 41 Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management.  Br J Haematol. 2003;  121 535-555
• 42 Blank M, Shoenfeld Y, Tavor S et al.. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.  Int Immunol. 2002;  14 121-129
• 43 Reiher F K, Volpert O V, Jimenez B et al.. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.  Int J Cancer. 2002;  98 682-689